Abstract：
BACKGROUND: The demand for nonsurgical facial rejuvenation options is growing, yet the periorbital region remains an area of relative unmet need. This review explores nonsurgical options for facial rejuvenation and the role of oxymetazoline hydrochloride ophthalmic solution, 0.1%, in treating age-related blepharoptosis as part of periorbital rejuvenation.
METHODS: Advisors experienced in facial rejuvenation met to discuss existing literature on the upper face and periorbital rejuvenation and the role of oxymetazoline hydrochloride ophthalmic solution, 0.1%, in treating facial aging.
RESULTS: An array of nonsurgical options exist to address the signs of aging, including minimally invasive treatments, such as botulinum toxin injections and dermal fillers, and noninvasive therapy, such as lasers, chemical peels, and microdermabrasion. However, treating age-related ptosis in periorbital rejuvenation is mainly addressed surgically. The newly approved α-adrenergic receptor agonist oxymetazoline hydrochloride ophthalmic solution, 0.1%, provides a novel non-interventional approach to blepharoptosis.
CONCLUSIONS: Facial rejuvenation is highly sought-after in this post-pandemic era. Each nonsurgical treatment option has its advantages and drawbacks. A patient-centered approach is necessary to select the appropriate procedure considering the patient\'s concerns and aesthetic sensibilities. The eyes are an area of primary concern for patients, yet surgery is the gold standard for treating ptosis. Oxymetazoline hydrochloride ophthalmic solution, 0.1%, is a safe and effective nonsurgical treatment for blepharoptosis.
METHODS: Advisors experienced in facial rejuvenation met to discuss existing literature on the upper face and periorbital rejuvenation and the role of oxymetazoline hydrochloride ophthalmic solution, 0.1%, in treating facial aging.
RESULTS: An array of nonsurgical options exist to address the signs of aging, including minimally invasive treatments, such as botulinum toxin injections and dermal fillers, and noninvasive therapy, such as lasers, chemical peels, and microdermabrasion. However, treating age-related ptosis in periorbital rejuvenation is mainly addressed surgically. The newly approved α-adrenergic receptor agonist oxymetazoline hydrochloride ophthalmic solution, 0.1%, provides a novel non-interventional approach to blepharoptosis.
CONCLUSIONS: Facial rejuvenation is highly sought-after in this post-pandemic era. Each nonsurgical treatment option has its advantages and drawbacks. A patient-centered approach is necessary to select the appropriate procedure considering the patient\'s concerns and aesthetic sensibilities. The eyes are an area of primary concern for patients, yet surgery is the gold standard for treating ptosis. Oxymetazoline hydrochloride ophthalmic solution, 0.1%, is a safe and effective nonsurgical treatment for blepharoptosis.
摘要：
背景：对非手术面部年轻化选择的需求正在增长，然而，眶周区域仍然是一个相对未满足需求的区域。这篇综述探讨了面部年轻化的非手术选择以及盐酸羟甲唑啉眼用溶液的作用，0.1%,治疗年龄相关性上睑下垂作为眶周恢复的一部分。
方法：在面部年轻化方面有经验的顾问开会，讨论有关上面部和眶周年轻化的现有文献以及盐酸羟甲唑啉眼用溶液的作用，0.1%,在治疗面部老化。
结果：存在一系列非手术选择来解决衰老的迹象，包括微创治疗，如肉毒杆菌毒素注射和皮肤填充剂，和非侵入性治疗，比如激光，化学果皮,和微晶换肤术.然而,在眶周恢复中治疗年龄相关性上睑下垂主要通过手术解决。新批准的α-肾上腺素受体激动剂盐酸羟甲唑啉眼用溶液，0.1%,提供了一种新的非介入性方法来治疗上睑下垂。
结论：在大流行后时代，面部年轻化非常受欢迎。每种非手术治疗方案都有其优点和缺点。以患者为中心的方法是必要的，以选择适当的程序考虑患者的关注和审美敏感性。眼睛是患者首要关注的领域,然而手术是治疗上睑下垂的黄金标准。盐酸羟甲唑啉眼用溶液，0.1%,是一种安全有效的非手术治疗方法。
方法：在面部年轻化方面有经验的顾问开会，讨论有关上面部和眶周年轻化的现有文献以及盐酸羟甲唑啉眼用溶液的作用，0.1%,在治疗面部老化。
结果：存在一系列非手术选择来解决衰老的迹象，包括微创治疗，如肉毒杆菌毒素注射和皮肤填充剂，和非侵入性治疗，比如激光，化学果皮,和微晶换肤术.然而,在眶周恢复中治疗年龄相关性上睑下垂主要通过手术解决。新批准的α-肾上腺素受体激动剂盐酸羟甲唑啉眼用溶液，0.1%,提供了一种新的非介入性方法来治疗上睑下垂。
结论：在大流行后时代，面部年轻化非常受欢迎。每种非手术治疗方案都有其优点和缺点。以患者为中心的方法是必要的，以选择适当的程序考虑患者的关注和审美敏感性。眼睛是患者首要关注的领域,然而手术是治疗上睑下垂的黄金标准。盐酸羟甲唑啉眼用溶液，0.1%,是一种安全有效的非手术治疗方法。
